Pyrimidine-2,4,5,6(1H,3H)-tetraone hydrate structure
|
Common Name | Pyrimidine-2,4,5,6(1H,3H)-tetraone hydrate | ||
---|---|---|---|---|
CAS Number | 2244-11-3 | Molecular Weight | 160.085 | |
Density | 1.681g/cm3 | Boiling Point | 374.1ºC at 760 mmHg | |
Molecular Formula | C4H4N2O5 | Melting Point | 255 °C (dec.)(lit.) | |
MSDS | Chinese USA | Flash Point | 180ºC | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Pyrimidine-2,4,5,6(1H,3H)-tetraone hydrateAlloxan hydrate is a diabetogenic agent to induce diabetes. Alloxan hydrate is a proteasome inhibitor. Alloxan causes diabetes in experimental animals through its ability to destroy the insulin-secreting B-cells of the pancreas[1][2]. |
Name | Alloxan monohydrate |
---|---|
Synonym | More Synonyms |
Description | Alloxan hydrate is a diabetogenic agent to induce diabetes. Alloxan hydrate is a proteasome inhibitor. Alloxan causes diabetes in experimental animals through its ability to destroy the insulin-secreting B-cells of the pancreas[1][2]. |
---|---|
Related Catalog | |
In Vitro | Alloxan hydrate inhibits the peptidase activities of the purified 26S and 20S proteasomes[1]. |
References |
Density | 1.681g/cm3 |
---|---|
Boiling Point | 374.1ºC at 760 mmHg |
Melting Point | 255 °C (dec.)(lit.) |
Molecular Formula | C4H4N2O5 |
Molecular Weight | 160.085 |
Flash Point | 180ºC |
Exact Mass | 160.012024 |
PSA | 115.73000 |
Vapour Pressure | 8.59E-07mmHg at 25°C |
Storage condition | 2-8°C |
Water Solubility | H2O: may be hazy yellow |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332 |
Precautionary Statements | P280 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn:Harmful; |
Risk Phrases | R20/21/22 |
Safety Phrases | S36 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | UW0492000 |
HS Code | 29335995 |
Precursor 0 | |
---|---|
DownStream 2 | |
HS Code | 2933599090 |
---|---|
Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predicti... |
Mesoxalylcarbamide monohydrate |
2,4,5,6-Tetraoxohexahydropyrimidine hydrate |
MFCD00149399 |
2,4,5,6-Tetraoxypyrimidine |
2,4,5,6(1H,3H)-Pyrimidinetetrone hydrate |
alloxan hydrate |
2,4,5,6(1H,3H)-Pyrimidinetetrone hydrate (1:1) |
ALLOXAN MONOHYDRATE |
alloxane monohydrate |
1,3-dihydropyrimidine-2,4,5,6-tetraone,hydrate |
2,4,5,6(1H,3H)-Pyrimidinetetrone, hydrate (1:1) |
Alloxan-monohydrat |
5,6-Dioxyuracil |
alloxane hydrate |
Alloxan,monohydrate |
Pyrimidine-2,4,5,6(1H,3H)-tetraone hydrate |
EINECS 251-501-8 |
Pyrimidine-2,4,5,6(1H,3H)-tetrone hydrate (1:1) |